Introduction: The coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) creates a global pandemic and affects more than 200 countries/regions. As of July 30, 2020, the cumulative number of confirmed cases of COVID-19 in the world exceeded 16 million. SARS-CoV-2-infected patients are more likely to be admitted to the hospital and enter the intensive care unit, with high mortality. The most common symptoms of COVID-19 patients are fever and cough. Objective: To assess the magnesium sulfate extended infusion as an adjunctive treatment for covid-19 infected for anaesthesia. Materials and Methods: The prospective study was undertaken Department of Anesthesiology, Medical College for women and Hospital, Uttara, Dhaka, Bangladesh from July to December 2021. Of the 157 anesthesiologists who responded to this survey, 57 (36.0%) reported using magnesium sulfate in anesthesia. All patients received standard therapy for asthma, while the treatment group received an intravenous magnesium sulfate bolus of 50-75 mg/kg (0.2-0.3 mmol/kg) followed by 40 mg/kg/h (0.16 mmol/kg/h) for 4 h. Patients were monitored for cardiorespiratory complications. The treatment group underwent four blood draws to assess pharmacokinetic parameters. Results: Of the 157 anesthesiologists who responded to this survey, 57 (36.0%) reported using magnesium sulfate in anesthesia. The highest participants 50 years above 48(30.5%), 31-40 years 28(17.8%) and 0-10 years 04(2.5%). The frequency of use of adjuvant drugs in anesthesia is described. The number and percentage of clinical effects (n/%) for the use of magnesium sulfate in anesthesia were (in descending order, more than one response per participant allowed): postoperative analgesia (41/71.9%), reduction of anesthetic consumption (59/68.4%), prevention and treatment of preeclampsia and seizures in eclampsia (36/63.1%), prevention and treatment of arrhythmias (29/50.8%), reduction of the dose .......